{
    "nctId": "NCT00068601",
    "briefTitle": "S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer",
    "officialTitle": "Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Infertility, Menopausal Symptoms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 257,
    "primaryOutcomeMeasure": "Rate of Premature Ovarian Failure at 2 Years",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast cancer\n\n  * Stage I-IIIA\n  * Operable disease\n* Bilateral synchronous invasive breast cancer allowed provided primary tumors were diagnosed no more than 1 month apart and both tumors are hormone receptor negative\n* Must be planning to receive 3-8 months of a preoperative or postoperative chemotherapy regimen containing alkylating agents (anthracyclines or non-anthracyclines), meeting 1 of the following criteria:\n\n  * 3-month/4-course anthracycline-based regimen\n  * 6- to 8-month/course anthracycline-based regimen\n  * 6- to 8-month/course non-anthracycline-based regimen\n* Hormone receptor status:\n\n  * Estrogen receptor negative\n  * Progesterone receptor negative\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 to 49\n\nSex\n\n* Female\n\nMenopausal status\n\n* Premenopausal\n\nPerformance status\n\n* Zubrod 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Not specified\n\nRenal\n\n* Not specified\n\nOther\n\n* Not pregnant or nursing\n* Fertile patients must use effective barrier contraception\n* No other prior malignancy except adequately treated basal cell or squamous cell skin cancer or any in situ cancer from which the patient has been disease-free for at least 5 years after treatment with curative intent\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* See Disease Characteristics\n* No prior cytotoxic chemotherapy\n\nEndocrine therapy\n\n* No other concurrent hormonal therapy\n\nRadiotherapy\n\n* Concurrent radiotherapy to the breast, chest wall, or lymph nodes allowed\n\nSurgery\n\n* See Disease Characteristics\n\nOther\n\n* Concurrent participation in other therapeutic clinical trials, including SWOG-S0221, allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}